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Background:  Purines constitute a structural class of protein ligands involved in 
mediating an astonishing array of metabolic processes and signal pathways in 
all living organisms. Synthesis of purine derivatives targeting specific purine- 
binding proteins in vivo could lead to versatile lead compounds for use as 
biological probes or drug candidates. 
Results: We synthesized several libraries of 2,6,9-trisubstituted purines using 
both solution- and solid-phase chemistry, and screened the compounds for 
inhibition of cyclin-dependent kinase (CDK) activity and human leukemic cell 
growth. Lead compounds were optimized by iterative synthesis based on 
structure-activity relationships (SARs), as well as analysis of several 
CDK-inhibitor cocrystal structures, to afford several interesting compounds 
including one of the most potent CDK inhibitors known to date. Unexpectedly, 
some compounds with similar CDK inhibitory activity arrested cellular 
proliferation at distinctly different phases of the cell cycle, and another inhibitor 
directly induced apoptosis, bypassing cell-cycle arrest. Some of these 
compounds selectively inhibited growth of cells derived from specific tumors. 
Conclusions: 2,6,9-Trisubstituted purines have various and potent biological 
activities, despite high concentrations of competing endogenous purine ligands 
in living cells. Purine libraries constitute a versatile source of small molecules 
that affect distinct biochemical pathways mediating different cellular functions. 
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I n t roduct ion  
Purines are ubiquitous molecules that exist at relatively 
high (millimolar) concentrations in living organisms. 
Guanine and adenine, two of the most common purines, 
are essential components of nucleic acids, cofactors and 
signaling molecules that modulate protein function. 
Indeed, more than 10% of the proteins encoded by the 
yeast genome evidently depend on a purine-containing 
ligand for their function (see the database search at http:// 
www.quest7.proteome.com) [1]. These include kinases, 
DNA (or RNA) polymerases, ATPase~, GTPases, purine 
receptors, and purine biosynthetic and metabolic enzymes. 
For this reason, diverse purine libraries might be xpected 
to have a high probability of yielding bioactive compounds 
when screened in a variety of enzyme- and cell-based 
assays. It seemed likely that structural variation at the 2, 6, 
8 and 9 positions might impart specificity towards a variety 
of target proteins. This possibility prompted us to explore 
purine libraries as a source of both drug leads and probes 
for analyzing complex cellular processes. 
We chose first to screen our purine libraries for inhibitors 
of the cyclin-dependent kinases (CDKs) because CDKs 
have recently attracted considerable interest in light of 
their essential role in regulating the cell cycle. The 
CDKs are in turn regulated by a variety of intracellular 
signals including the binding of inhibitory factors, phos- 
phorylation and cellular localization. Previously, a 
number of purines, as well as nonpurine compounds, 
such as olomoucine and staurosporine have been devel- 
oped as CDK inhibitors, but they suffer from potency or 
selectivity problems, respectively (Figure 1). For 
example, purine analogs uch as olomoucine and roscovi- 
tine have been shown to selectively inhibit a subset of 
the CDKs (olomoucine has an ICs0 value of 7 ~M against 
both CDK1 and CDK2 [2], and roscovitine has IC50 
values of 0.65 and 0.7 ~xM against CDK1 and CDK2 [3]). 
A 2.4 A- resolution X-ray crystal structure of olomoucine 
bound to CDK2 revealed that the purine ring occupies 
the conserved ATP-binding pocket [4]. Unexpectedly, 
however, the purine ring of olomoucine is rotated nearly 
180 ° with respect o that of ATP. Although the interac- 
tions between the amino-acid residues in the binding site 
are different for olomoucine and ATP, the amount of 
solvent-accessible surface that becomes buried is similar 
for the two ligands. 
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Structures of olomoucine, roscovitine, flavopiridol and staurosporine. 
Although CDK1 and CDK2 serve different functions in 
controlling cell-cycle progression [5], the binding affinities 
of synthetic inhibitors [3] and the structures of their 
ATP-binding pockets are nearly identical, on the basis of 
amino-acid sequence [5]. Starting with the CDK2-olo- 
moucine model, our goal is to use combinatorial chemistry 
to generate selective high-affinity inhibitors for CDK1 and 
CDK2, as well as other key cellular kinases, by introducing 
substituents at the 2, 6 and 9 positions of the purine ring. 
We and others previously reported several strategies for 
the solution- or solid-phase synthesis of purine derivatives 
[6-11], and have assayed these compounds against CDKs 
to determine structure-activity relationships (SARs). Our 
previous solid-phase synthesis cheme required that one 
position of the purine ring be held invariant to allow 
attachment to the solid support (Figure 2). Two positions 
were then varied combinatorially in order to identify 
optimal substituents in a pairwise fashion. In general,' the 
effects of substituents at the 2, 6 and 9 positions on 
binding affinity appear to be additive, allowing one to 
rapidly identify potent purines by combining optimal sub- 
stituents identified from simple binary libraries. 
We describe new solid- and solution-phase syntheses of 
2,6,9-trisubstituted purine libraries that can be used to 
combine rapidly and efficiently those substituents identi- 
fied in the primary screens to afford second-generation 
libraries. Several specific and highly potent CDK2/CDK1 
Figure 2 
inhibitors have been identified from these libraries. In 
addition we characterized the cell-cycle inhibitory activi- 
ties of a number of highly potent CDK inhibitors and 
found that some compounds arrested cellular proliferation 
at distinctly different phases of the cell cycle. 
Results and discussion 
Solid-phase synthesis 
We used the crystal structures of various CDK2-1igand 
complexes to design the initial binary libraries with 
respect o the steric and electronic properties of the sub- 
stituents to be introduced at the 2, 6 and 9 positions. A 
comparative analysis of the binding mode of olomoucine, 
flavopiridol [12] and staurosporine [13] in the ATP- 
binding pocket of CDK2 provided important information 
about functional groups that could be accommodated. For 
example, comparison of the bound purines and flavopiri- 
dol/staurosporine r vealed that substituents at the 2 or 9 
position of the purine ring might be able to occupy the 
same region of the active site as does the N-methyl 
piperidyl ring of flavopiridol (Figure 3c). 
Synthesis and assays of the binary libraries against CDK2 
indicated that aniline and 3- and 4-substituted benzylamine 
substituents led to significant improvements when intro- 
duced at the 6 position of the purine ring. Although a variety 
of hydroxyalkylamino, dihydroxyalkylamino and cycloalky- 
lamino substituents at the 2 position resulted in moderate 
improvements, greater improvements were achieved with 
amino alcohols derived from valine and isoleucine. In con- 
trast to many other protein kinases that can accommodate 
larger substituents at the 9 position of the purine ring, 
CDK2 binding was strongest for those purines bearing iso-
propyl functionality, followed by ethyl or hydroxyethyl [6]. 
Our previous ynthetic routes involved tethering the purine 
core to the solid support hrough either a glycinamido, a
4-aminobenzyl amino or a 2-hydroxyethyl group at the 2, 6 
and 9 positions, respectively. The drawback of these 
approaches i that one potential combinatorial site is lost. 
To circumvent this limitation a new solid-phase strategy 
and a versatile solution-phase route were developed. The 
solid-phase synthesis allows the introduction of substituents 
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Precursors for binary library solid-phase 
synthesis. 
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Figure 3 
Purvalanol B bound to CDK2 (black sticks, 
principal conformation only) is compared with 
(a) bound olomoucine (white sticks) and 
bound roscovitine (orange sticks), (b) bound 
ATP (yellow sticks), (c) bound flavopiridol 
(green sticks) and (d) bound staurosporine 
(purple sticks). The comparisons are based on 
superposition of the C a atoms of CDK2. The 
ligands are shown in ball-and-stick 
representation with carbon atoms in white, 
nitrogen atoms in blue, oxygen atoms in red, 
phosphorous atoms in violet and the chlorine 
atoms of purvalanol B in green. 
(b) 
' ° '  x . 
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at the 2, 6 and 9 positions by immobilizing the purine 
through the N6 amino group. This is accomplished by 
starting with a library of resin-bound amines obtained from 
the reductive amination of a 5-(4-formyl-3,5-dimethoxy- 
phenyloxy)valeric acid (BAL)-derivatized solid support 
with a collection of primary amines. By treating the resin- 
bound amines with a purine activated for substitution at 
the 6 position, combinatorial modification at the 6 position 
is achieved. Modification of the N9 and C2 positions i  
then accomplished using Mitsunobu and amination chem- 
istry as described previously (Figure 4) [7]. 
The synthetic scheme outlined above required that the 
electrophilicity of the purine ring be increased so that the 
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Figure 4 
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General scheme for solid-phase synthesis. 
first amination reaction at the 6 position of the purine could 
be performed with weakly nucleophilic and or-branched 
amines. In order to facilitate the ability of a secondary 
amine to displace the 6-chloro group, we acylated the N9 
position, which is expected to increase the overall elec- 
trophilicity of the purine ring. Unfortunately, the resulting 
activated amido group is more susceptible to nucleophilic 
attack than the 6-chloro group in the subsequent amination 
reaction. Another group that activates the 6 position of the 
purine ring without itself being susceptible to nucleophilic 
displacement is a N9-substituted tetrahydropyranyl (THP) 
aminal. Unfortunately, the acid lability of most commer- 
cially available solid supports made it difficult to cleave the 
THP group selectively without the concomitant release of 
the purine core. We therefore turned our attention to an 
N9-trimethylsilylethoxymethyl (SEM) activating group 
Figure § 
that is stable to amino nucleophiles and can be cleaved 
using fluoride under nonacidic onditions. The N9-SEM-2- 
fluoro-6-chloro purine 1 (Figure 5) was prepared (in 50% 
yield) by alkylation of 2-fluoro-6-chloropurine [7], with 
SEM-C1 in the presence of Hunig's base. This substitution 
significantly increased the reactivity of the ring system to 
amination, allowing an amination reaction with benzy- 
lamine to proceed at room temperature (which had previ- 
ously required extended heating at 50°C). 
The optimized scheme starts with the reductive amination 
of BAL-derivatized 4-methylbenzhydrylamine (MBHA) 
resin to give resin bound amine, R2 [7]. A variety of amines 
including alkylamines, benzylamines and anilines were 
used in this first step. The purine core is then loaded onto 
solid support by reacting 2equivalents of 1 with the amine- 
derivatized solid support R2, at 50°C to give R3. The 
removal of the SEM protecting roup was performed using 
0.25 M tetrabutylammonium fluoride in THF  at 60°C. The 
deprotected purine was then reacted with various alcohols 
and amines at the 9 and 2 positions using Mitsunobu and 
nucleophilic-substitution chemistry respectively, as is 
shown for 2-(3-hydroxypropylamino)-6-(4-methoxybenzyl- 
amino)-9-isopropylpurine (209; Figure 5). 
Although we have used this solid-phase chemistry to 
prepare a variety of 2,6,9-trisubstituted purines, there are 
two limitations to this approach. First, secondary amines 
cannot be introduced at the 6 position because one nitro- 
gen substituent is required to attach the amine to solid 
support. More significantly, amination at the 2 position 
with bulky groups proceeded in low yield, perhaps due to 
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Representative scheme for solid-phase 
chemistry. (i) SEM-Cl (1.2 eq), DIEA, DMF, 
0°C --> rt. (ii) p-methoxybenzylamine, 
NaBH(OAc)3, AcOH (2%), DMF, rt. (iii) DIEA, 
nBuOH-DMSO (1:1) 50°C. (iv) TBAF 
(0.25 M), THF, 60~C. (v) iPrOH (0.5 M), DIAD 
(0.5 M), PPh 3 (1.0 M), THF-CH2CI 2 (1:1). 
(vi) 3-amino-1-propanol, DIEA, N-methyl- 
pyrrolidinone, 110°C. (vii) TFA-water (95:5), rt. 
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Figure 6 
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General schemes for solution-phase synthesis. 
the decreased reactivity of purines attached to solid 
support. To overcome these limitations, we developed two 
versatile solution-phase synthetic routes to diverse trisub- 
stituted purines. 
Solution-phase synthesis 
In route I (Figure 6), 2-amino-6-chloropurine was func- 
tionalized sequentially at the 9, 2 and 6 positions. Sub- 
stituents at N9 were introduced by regioselective 
alkylation with a primary or secondary alcohol under Mit- 
sunobu conditions [14]. In order to render the 2 position 
sufficiently acidic to undergo Mitsunobu alkylation, it was 
first acylated with trifluoroacetic anhydride. The trifluo- 
roacetyl group is conveniently removed by hydrolysis with 
aqueous potassium carbonate prior to purification of the 
alkylated product by chromatography. Finally, a variety of 
primary and secondary benzylamines or anilines are intro- 
duced at the 6 position by reacting 3 with 1-2 equivalents 
of amine in n-butanol at elevated temperatures (Figure 7) 
(primary amines require 60°C whereas secondary mines 
and anilines require 110-120°C). 
Figure 7 
In route II (Figure 6), 2-fluoro-6-chloropurine was func- 
tionalized sequentially at the 9, 6 and 2 positions. As 
before, substituents at N9 position were introduced by 
Mitsunobu alkylation with either primary or secondary 
alcohols. This alkylation reaction tolerates virtually any 
alcohol without additional acidic hydrogens (pKa < 10-12). 
The more electrophilic 6-chloro substituent was selec- 
tively substituted with one equivalent of a benzylamine or 
aniline in analogy to route I. The resulting 2-fluoro- 
6,9-disubstituted purines were purified either by chro- 
matography on silica or if solubility permitted, by 
trituration with dichloromethane and 0.1N aqueous 
hydrochloric acid. Finally, the 2-fluoro position was ami- 
nated using an excess of primary or secondary amines in a 
small volume of n-butanol typically in a sealed tube 
(Figure 8). Representative procedures for two members of 
a purine library, 42 (synthesized by route I) and 60 (syn- 
thesized by route II), arc shown in Figure 7 and 8. 
CDKl/Cyclin B inhibition assay 
Due to the limited information available concerning the 
N9 position SARs, we prepared a library to focus on this 
site. Libraries of 2-fluoro-6-(4-aminobenzylamino)-9- 
alkylpurines were synthesized using a 4-aminobenzyl- 
amino linkage strategy on resin-derivatized pins (Figure 2) 
[7]. In order to allow direct comparison of the efficacy of a 
range of substituents at the N9 position, a portion of the 
library was cleaved prior to amination at the 2 position. As 
can be seen from the assay results, optimal CDK2 
inhibitory activity is observed for small alkyl groups with 
isopropyl exhibiting enhanced activity relative to ethyl, 
methyl and cyclopentyl (Figure 9). A similar result was 
obtained with another series of purines substituted with 
(2R)-pyrrolidin-2-yl-methanol at the C2 position [15]. 
To further enhance the CDK affinity of purine derivatives 
identified in previous screens of first-generation purine 
libraries, the synthetic methods described above were iter- 
atively applied to the 2, 6 and 9 positions, and compounds 
were tested for activity against starfish oocyte CDK1/cyclin 
B [3]. Based on the improved activities of a 9 position iso- 
propyl over methyl, and aniline over the benzyl group of 
olomoucine, we first derivatized the 9 position with an iso- 
propyl substituent and tested various aniline suhstituents 
at the 6 position (Figure 10). Among the 2,3,4-substituted 
anilines, the 3-chloroaniline derivative 52 is the best CDK 
Representative scheme I for solution chemistry. 
(i) iPrOH (2.0 eq), DEAD (1.1 eq), PPh 3 
(2.0 eq),THF, -10 -~ 25°C. (ii) (CF3CO)20, 
CH2CI 2, 0 --> 25°C. (iii) TBDMSOCH2CH2OH 
(2.0 eq), DEAD (1.0 eq), PPh 3 (2.0 eq), THF, 
0 --~ 25°C. Then K2003, MeOH. (iv) aniline 
(4.0 eq), DIEA, nBuOH, 110°C. Then AcOH- 
H20-THF (3:1:1). 
CI 
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Figure 8 
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Representative scheme for solution chemistry II. (i) iPrOH (1.2 eq), 
DEAD (1.3 eq). PPhz (1.3 eq), THF -10 --~ 25°C. (ii) 3-chloroaniline 
(1.0 eq), DIEA, nBuOH, 140°C. (iii) (R)-(-)-2-amino-3-methyl-1-butanol 
(1.5 eq), DIEA, nBuOH, 150-170°C in sealed tube. (iv) Mel (2 eq), 
Nail, DMF, ft. (v) Boc20, DIEA, DMAP, THF, rt. (vi) (R)-(-)-2-amino- 
3-methyl-1 -butanol (1.2 eq), DIEA, DMSO, 70-80°C. (vii) TBDMS-CI, 
imidazole, DMAP, THF, rt. (viii) BnBr, Bu4NI, Nail, DMF. Then pTSA, 
MeOH-CH2CI2, rt. 
inhibitor, showing a 30-fold improvement over olo- 
moucine (with an ICs0 value of 220 nM). The 3-bromo, 
fluoro and trifluoromethyl groups exhibited <zomparable 
Figure 9 
activities, whereas the same 2-substituted purines are 
tenfold less active. 
Next, we explored variations at the 2 position with the 6 
position derivatized with either 4-methoxybenzylamine, 
the best among the benzyl substituents or 3-chloroaniline, 
chosen from the first-round solution-phase synthesis 
(Figure 11). Many compounds that have moderate activity 
(100-1000 nM) were found in this series. In general, we 
observed a preference for hydroxyalkyl or dihydroxyalkyl 
groups at the 2 position. An eightfold improvement in the 
IC50 value, however, was obtained by replacing the 2 posi- 
tion hydroxyethylamino (52) with R-valinol attached via 
the 0~-amino group (60, named purvalanol A). In agree- 
ment with other reports [3], compounds with the R-stereo- 
chemistry were 2-16-fold more potent han those with the 
S-stereochemistry (75 versus 76, 60 versus 58, 66 versus 59 
and 68 versus 69). Although most of the cyclic secondary 
amines were in general not preferred at 2 position, 
2-hydroxyethylpiperidyl (10) improved the inhibitory 
activity threefold over hydroxyethyl (118). 
In the third round, we fixed the 2 position with the 
R-valinol substituent, and refocused attention to the 
6 position with a variety of benzylamine and aniline 
groups (Figure 12). This resulted in a set of the most 
active small-molecule CDK inhibitors known to date. The 
halogens on the 3 and 4 positions significantly improved 
the activity, and both the activity and solubility were 
enhanced with an additional carboxylate or amino group. 
In parallel with the third round, we also fixed the 2 posi- 
tion with 2-(2-hydroxyethyl)piperidyl substituent and 
derivatized the 6 position with various benzylamine and 
aniline substituents (Figure 13). Simple aniline (220) or 
100 JF~.~ I~ .. - 
I l l  
° 1 
~ 20 
0 - - , i , , - • , • , . , , 
1 3 5 7 9 11 13 15 17 19 21 23 25 27 
Compound number Chemistry &Biology 
CDK2/cyclin A activity for representative 
compounds from an N9-directed library. 
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Figure 10 
SAR class 1. Various C6-substituents on a 
2- (2-hydroxyethylamino)-9-isopropylpurine core. 
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benzylamine (212) substituents proved to be slightly 
better than 4-methoxybenzylamine (10). Although 4-sub- 
stituted benzylamine was tolerated (216), 3-substituted 
benzylamine (113, 222) decreased the activity signifi- 
cantly. Linear alkyl substituents (219), bulky substituents 
(225, 226, 227) and substituted anilines (359, 306) also 
decreased the activity. 
During these rounds of optimization, we relied on the 
approximate additivity of substituents. The observed addi- 
tivity allowed us to more efficiently assess greater numbers 
of substituents at a single site, thereby enhancing our 
ability to explore each of the binding sites without having 
to make all combinatorial possibilities. In this format, eval- 
uation of 10 substituents at each site requires three sets of 
10 compounds rather than one set of 1000. The simplest 
explanation for the observed additivity is that the rigid 
purine scaffold prevents ubstituents atthe 2, 6 and 9 posi- 
tions from binding in overlapping regions of the active site. 
One of our most potent inhibitors, purvalanol B (95; 
Figure 12), was cocrystalized with CDK2 (Figure 14) [16], 
and the structure was compared with the structures of 
CDK2-flavopiridol, CDK2-staurosporine and CDK2- 
ATP (Figure 3). Purvalanol B occupied 86% of the avail- 
able space in the binding pocket of CDK2, whereas 
flavopiridol occupied 74%, ATP occupied 78% and olo- 
moucine occupied 76%. 
Another of the most potent inhibitors, aminopurvalanol (97; 
Figure 12) was tested for its activity against a variety of 
kinases (Table 1). As expected, aminopurvalanoI had 
almost he same activity against CDK1 as CDK2, with ICs0 
values ranging from 28-33 nM. Among the enzymes tested, 
only CDK5/p35 was inhibited to the same extent as CDK1/ 
CDK2, whereas other kinases exhibited much weaker inhi- 
bition by 97. The high degree of specificity observed for 97 
is similar to that observed for purvalanol A and B [16]. 
The crystal structures of CDK2 with purvalanol B, ATP, 
flavopiridol or staurosporine suggested that additional con- 
tacts could be introduced by appending an extra group at 
the N2 position of purvalanol B (Figure 14). We therefore 
attempted to synthesize N2-disubstituted derivatives of 60 
by amination of 2-fluoro-6-(3-chloroanilino)-9-isopropyl- 
purine (5) with N-alkyl valinol derivatives. Several N-alkyl 
valinol derivatives were synthesized by reductive alkylation 
of valinol with a variety of alkyl, aromatic and heteroaro- 
matic aldehydes using sodium triacetoxyborohydride in 
1,2-dichloroethane. Unfortunately, these branched sec- 
ondary amines could not be installed at the 2 position, pre- 
sumably due to their steric bulkiness. Attempts to activate 
the 2-fluoro group by introducing an electron withdrawing 
tert-butoxycarbonyl (Boc) group at the 6-position also failed 
to promote nucleophilic substitution. Finally, the O-silyl 
and 6-N-Boc protected erivative, 9, was successfully alky- 
lated using sodium hydride, alkyl halide and tetrabutylam- 
monium iodide in dimethvlformamide (Figure 8). The 
desired compounds were obtained by removing the protect- 
ing groups and tested against CDK1/cyclin B. Unexpect- 
edly, this class of compounds showed substantially reduced 
activity (with an ICs0 value between 5 and 10/.tM; Figure 
15). This is not simply a consequence of disubstitution at 
the 2 position because 2-bishydroxyethyl derivatives uch 
as 16, 26, 211, 303, 04 and 305 (IC50 220-350 nM) show 
comparable activity to their parent hydroxyethyl derivatives 
118 (IC50 700nM), and 52 (ICs0 220nM; Figure 11). 
Potentially the combination of the sterically hindered 
R-valinol with additional substitution at the 2 position may 
prevent he inhibitors from accessing a productive binding 
conformation. Alternatively, the hydrophobic N-alkyl 
valinol derivatives that we introduced at the 2 position 
might have been poorly suited to the binding site. 
For many of the biological applications described in the 
next section, we wanted access to a collection of negative 
control compounds that were structurally very. similar to 
our potent inhibitors but lacked CDK inhibitory activity. 
We could then use these inactive derivatives to test if an 
observed in vivo effect is correlated with in vitro CDK 
activity. From the cocrystal structure of purvalanol B with 
CDK2 it was apparent that addition of a methyl group to 
N6 should lead to significantly reduced CDK inhibitory 
activity due to steric hindrance and the loss of a hydrogen 
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SAR class 2. Various C2-substituents on a 
6-(4-methoxybenzylamino)- or a 
6-(3-chloroanilino)-9-isopropylpurine core. 
bond to Leu83 (Figure 14). We synthesized N6-methy- 
lated derivatives of four of our most potent CDK 
inhibitors (52, 60, 97 and 212; Figure 8). As expected, 
these compounds (52Me, 60Me, 97Me and 212Me) are 
completely inactive as CDK1/cyclin B inhibitors in vitro. 
Cellular effects and cell cycle studies 
We investigated the biological activity of the most potent 
CDK inhibitors from each SAR class by testing their ability 
to inhibit growth of U937 human leukemic ells. Cell pop- 
ulations were treated with the various compounds, and 
then assayed for the percentage decrease in the number of 
viable cells, using the 3-(4,5-dimethylthiazole-2-yl)-2,5- 
diphenyl-2H-tetrazolium bromide (MTT) assay [17]. The 
most potent CDK inhibitors in SAR classes 2 and 3 
(Figures 11 and 12), compounds 60 and 97, were also found 
to be active inhibitors of cell growth (with lCs0 values of 
7.5 and 5 ~tM, respectively). The significant increase in the 
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Figure 12 
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cell-based ICs0 values relative to the in vitro IC50 values is 
presumably a result of competition with high concentra- 
tions of intracellular ATP (estimated to be in the millimo- 
lar range). Indeed when the kinase assay concentration of
ATP was increased from 15 pM to 1.5 mM, the IC50 value 
for compound 60 increased (as expected) from 4 nM to 
500 nM [16]. Compounds 94 and 95 were equally active in 
the kinase assay but inactive in vivo, probably due to the 
decreased cell permeability resulting from the negatively 
charged carboxylate group. From SAR class 4 (Figure 13), 
212 is both a potent inhibitor of CDK activity and of cell 
growth (ICs0 = 2.5 pM). 
To study the specific effects of different purine derivatives 
on cell-cycle progression, unsynchronized proliferating 
U937 cells were treated with compounds 60, 97, 212 and 52. 
Treated cells were then subjected to cell-cycle analysis 
using flow cytometry and to morphological nalysis using 
fluorescence microscopy. For flow cytometry, unsynchro- 
nized cell populations were labeled with propidium iodide 
(PI), a fluorescent DNA intercalator, and for the TUNEL  
assay, with a marker of DNA fragmentation that is charac- 
teristic of apoptosis. For morphological nalysis, cells were 
labeled with Hoescht 33258, a DNA-specific dye, and with 
an antitubulin antibody that could be visualized using a 
FITC-conjugated secondary antibody. Using dose-response 
and time-course assays, differences in the effects of the 
compounds due to variations in compound permeability or 
the kinetics of the cellular esponse were investigated. 
Initially, U937 cell populations were examined after treat- 
ment with 97 or 60, the most potent and bioactive CDK 
inhibitors. By flow cytometry, treatment of cells with 97 or 
60 at doses lower than 10 btM specifically arrested cells in 
the G2-M phase of the cell cycle, based on the accumula- 
tion of cells with a 4 N DNA content, and the absence of 
DNA fragmentation (Figure 16). At higher concentrations 
(> 20 l.tM), however, both 97 and 60 triggered apoptosis 
after 8 h treatments, as detected with the TUNEL  assay 
and confirmed by the appearance of nucleosome-sized 
DNA ladders as assessed by electophoresis (data not 
shown). The only apparent difference between the effects 
conferred by 60 or 97 to proliferating U937 cells related to 
their specific activity: 97 was four times more active than 
60 in inducing a G2-M cell-cycle arrest (with ICs0 values 
of 1.25 pM and 5 }.tM, respectively). The effect of 97 and 
60 on microtubule architecture and on chromatin conden- 
sation were consistent with G2 cell-cycle arrest, based on 
the low percentage of mitotic cells (< 5%) seen in the 
treated populations. Because entry into mitosis depends 
on CDK1/CDK2 activity [18], inhibition of the G2-M 
phase transition was the expected result, based on the 
high activity of the compounds against CDK in vitro. 
Indeed, cells treated with either compound displayed 
fibrous microtubule organization, decondensed chromatin 
and intact nuclear architecture characteristic of interphase 
cells. Nevertheless, consistent with centrosome duplica- 
tion occurring independently of CDK1 activity [19], a sig- 
nificant fraction of cells possessed two distinct 
Figure 13 
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microtubule arrays nucleated by discernible microtubule- 
organizing centers (Figure 17). In the presence of 97, 
these duplicated microtubule-organizing centers nucle- 
ated long microtubules characteristic of interphase cells. 
In the presence of 60, some of the microtubule arrays 
appeared shorter and more polarized, reminiscent of half 
spindles without attached chromosomes. Based on these 
results, the effects of compounds 60 and 97 on proliferat- 
ing U937 cells appeared consistent with their specific 
CDK1/CDK2 inhibitory activity. 
The CDK inhibitory activity of compounds 60 and 97 
was significantly different from that of 52, the most 
Table 1 
Inhibition of purified kinases by aminopurvalanol (97). 
Kinase IC5o (uM) 
CDKl/cyclin B 0.033 
CDK2/cyclin A 0.033 
CDK2/cyclin E 0.028 
CDKS/p35 0.020 
Erkl 12.0 
Erk2 3.1 
c-Raf >1 O0 
MAPKK >1 O0 
PKC-~ >1 O0 
PKC-[~I >1 O0 
PKC-~2 > 1 O0 
PKC-7 >100 
PKC-5 36.0 
PKC-~ >1 O0 
PKC-q >100 
PKC-~ >1 O0 
PKA 18.0 
PKG >1 O0 
Casein kinase 1 3.0 
Casein kinase 2 >100 
Insulin receptor Tyr-K 4.4 
potent CDKI  inhibitor from SAR class 1 (Figure 10). By 
flow cytometry, 52 affected cell-cycle progression at con- 
centrations of 25 uM or greater. Unlike cells treated with 
60 or 97, however, cells treated with a comparable con- 
centration of 52 did not become apoptotic (Figure 16b) 
and did not exhibit the characteristic accumulation of 
cells with a 4 N DNA content indicative of a G2 arrest. 
Instead, 52-treated cell populations displayed a repro- 
ducible depletion of the late-S/early-G2 cell population 
(Figure 16a). Morphologically, more than 20% of the cell 
population treated with 52 had bipolar microtubule spin- 
dles and condensed chromosomes, compared with less 
than 5% in control cell populations. This indicates that 
treatment of U937 cells with 52 causes arrest at mitosis. 
Interestingly, all of the 52-arrested, mitotic cells were in 
metaphase, as judged by the presence of two centro- 
somes, which nucleated polarized microtubules that were 
oriented towards each other, and fully condensed chro- 
mosomes aligned at the equator. Given the structural 
Figure 15 
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SAR class 5. Various C2-substituents on a 2-((1R-isopropyl)- 
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Figure 16 
Flow cytometric analysis of (a) cell-cycle 
distribution and (b) apoptosis in ug37 cell 
populations treated with different CDK 
inhibitors and their inactive, N6-methylated 
analogs. For each experiment, cells were 
treated for 0, 2, 4, 6 or 8 h, with increasing 
concentrations of compounds. Plots represent 
the most specific effect of each compound, as 
determined with the dose-response and time- 
course assays. For all the experiments, cells 
were co-labeled with PI, to stain the DNA, and 
with the TUNEL assay, to incorporate FITC- 
labeled nucleotides onto the ends of DNA 
fragments resulting from the apoptotic 
process. (a) Plots showing the distribution of 
cells with different DNA contents, after 8 h 
treatment with 5 ~tM 97 or 97Me, 10 t.tM 60 
or 60Me, 50 ~tM 52 or 52Me or 5 ~tM 912 or 
212Me. Bars indicate approximate DNA 
contents of cells with a 2N (D), intermediate 
(E) and 4N (F) DNA content, characteristic of 
cells in G1, S or G2-M phases of the cell 
cycle, respectively. DNA distribution of 
untreated cell populations are similar to those 
treated with the inactive, N6-methylated 
derivatives. (b) Bivariate plots of FITC versus 
PI staining of the same cell populations as in 
(a). Note that 212 is the only compound that 
nonspecifically induces apoptosis throughout 
the cell cycle without changing the cell-cycle 
distribution of the treated cell population. 
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similarity between compounds 52 and 60, we were sur- 
prised by their different effects on cells. 
The effect of 212, one of the most potent CDK inhibitors 
from SAR class 4 (Figure 13), on proliferating U937 cell 
populations was also different from that of 52, 60 or 97. 
Flow cytometric analysis revealed that compound 212 was 
a nonspecific inducer of apoptosis at concentrations as 
low as 5 gM: it triggered DNA fragmentation atall phases 
of the cell cycle, without affecting cell-cycle progression 
(Figure 16). With the TUNEL  assay, the effects of 212 
could be observed at concentrations as low as 2.5 ~M, 
making this compound one of the most potent inducers of 
apoptosis in the library. The induction of apoptosis was 
confirmed by the electrophoretic demonstration of nucle- 
osome-sized DNA from the 212-treated cells (data not 
shown). Morphologically, cells treated with 212 exhibited 
characteristic apoptotic features, such as condensed 
DNA, fragmented nuclei and little microtubule staining 
(Figure 17). By phase-contrast microscopy, cellular frag- 
mentation was also apparent (data not shown). 
As controls, the N6-methylated derivatives of 52, 60, 97 and 
212 were tested side-by-side with the respective active non- 
methylated compounds. At the same concentrations a the 
active analogs, none of the control compounds induced the 
cell-cycle effects, apoptosis, nor the abnormal microtubule 
features (Figures 16,17). It appears, therefore, that although 
closely related purine derivatives had ifferent effects 
when tested on cultured cells, the effects of the compounds 
on cell-cycle progression were specifically related to their 
chemical structure and their CDK-inhibitory activity. Previ- 
ously, treatment of cells with olomoucinc or roscovitine had 
been reported to lead to a G1/S and G2/M cell cycle arrest 
by a single mechanism [12,20,21]. In contrast, the different 
effects of these more potent and specific CDK inhibitors 
indicates a broader spectrum of activity. It remains to be 
determined whether the selectivity of different purines is 
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Figure 17 
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Morphological analysis of U937 cells treated 
with different CDK inhibitors and their inactive, 
N6-methylated analogs. For these experiments, 
cells were treated with the selected 
compounds for 6 h. Cells were then stained 
with fluorescein antitubulin 
immunocytochemistry o label the microtubules 
(green) and with the DNA-specific dye 
Hoescht 33258 to label the chromatin (blue). 
Samples were analyzed under the 
fluorescence microscope. Insets show the 
representative morphology of cells possessing 
duplicated microtubule organizing centers. In 
60 and 97, arrows indicate the abnormal, 
interphase-like microtubule arrays nucleated 
from these duplicated microtubule organizing 
centers. Note that he chromatin remains 
decondensed in these cells. Unlabeled cells 
are those with interphasic microtubule arrays 
and decondensed chromatin. M, cells with 
mitiotic bipolar spindles and condensed 
chromosomes. A, cells with apoptotic features 
such as condensed or fragmented nuclei 
accompanied by little microtubule staining. 
related to the specific molecular mechanism of cell-cycle 
deregulation accompanying cellular transformation. 
Cell-type selectivity study 
Because different tumors are characterized by genetic 
defects affecting different cell-cycle regulatory pathways, it
has been hypothesized that compounds that act upon a spe- 
cific pathway might be able to selectively inhibit growth of 
a particular tumor. Given the multiplicity of cell-cycle 
inhibitory activities exhibited by the purine inhibitors 
described, it seemed plausible that different purines would 
show selective growth-inhibitory activity against different 
tumor cell lines. Several active purines (60, 75, 95, 97 and 
Table 2 
Giso values for selected cancer cell lines (pM). 
52 60 75 97 212 
IGROV1 6.9 0.98 5.0 0.47 0.79 
(ovarian cancer) 
SR 7.6 1.9 2.3 0.42 4.7 
(leukemia) 
NCI-H522 2.6 0.35 1.9 1.0 1.4 
(lung cancer) 
KM12 ?.4 0.076 1.4 0.030 1.2 
(colon cancer) 
Average GIso* 14 2.0 3.7 1.8 2.1 
Average TGF 53 10 17 8.1 9.8 
Average LCso* 91 66 65 35 35 
*GIs0, growth inhibitory effect, tTGI, cytostatic effect. *LC50, cytotoxic 
effect. 
212) were therefore s lected for testing against he National 
Cancer Institute (NC1) panel of 60 cancer cell lines derived 
from different tumors. Cell growth inhibitory and cytotoxic 
activities of the compounds were found in the micromolar 
to nanomolar range. Although 75 and 212 were less selec- 
tive to different cell types, 60 and 97 showed significant 
selectivity to KM12 colon cancer cells (Table 2). Com- 
pound 95 did not show significant cytotoxicity in these cell 
lines, presumably due to its decreased cell permeability. 
Significance 
Purine ligands are bound by a tremendous variety of 
enzymes in living organisms. Synthetic purine derivatives 
with diverse substituents may have the ability to bind 
selectively to one class of purine-recognizing enzymes. We 
synthesized several hundred 2,6,9-trisubstituted purine 
derivatives using solid- and solution-phase chemistry and 
screened them for inhibition of cyclin-dependent kinase 
(CDK1)/cyclin B. In addition to finding several highly spe- 
cific and potent CDK inhibitors, we identified several com- 
pounds that elicited significantly different effects when 
tested in living cells. Compounds 60 (purvalanol A) and 97 
(aminopurvalanol) arrest the cell cycle specifically in the 
G2 phase and induced morphological features consistent 
with their observed CDK1/CDK2 inhibitory activity. In 
contrast, compound 52, a moderate CDK inhibitor, 
induced M-phase arrest, and compound 212, also an active 
CDK inhibitor, induced apoptosis independent ofcell-cycle 
phase. This broad spectrum of biological activities uggests 
that different purines might selectively act on different bio- 
chemical pathways affecting cell-cycle progression. 
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The degree of specificity exhibited by some of these 
purines, in terms of their ability to inhibit he cell-division 
cycle at different stages, is quite remarkable. Indeed, both 
structure-activity relationship (SAR) studies and the 
complete inactivity of the N-methylated analogs indicate 
that the effects of the different compounds are closely 
related to their chemical structures and to their CDK 
inhibitory activity. One possible interpretation of how 
similar CDK inhibitors display different cell-cycle 
inhibitory activities is that they are inhibiting different 
kinases in vivo. Alternatively, they might be inhibiting dif- 
ferent activities of the same CDK, complexed with spe- 
cific cyclins conferring different substrate specificities. 
Materials and methods 
Representative solution phase synthesis 
2-Amino-6-chloro-9-isopropylpurine (2a). Anhydrous THF (120 ml) 
was added to a flame-dried flask under nitrogen containing 2-amino-6- 
chloropurine (2.0 g, 11.8 mmol) and triphenylphosphine (6.2 g, 
23.6 mmol). To this wan added 2-propanol (1.4 ml, 23.6 mmol), after 
which the solution was stirred and cooled to -10°C using an ethylene- 
glycol/dry-ice bath. Following the dropwise addition of diethyl azodicar- 
boxylate (2.0 ml, 13.0 mmol), the mixture was gradually warmed to rt. 
After 24 h, the reaction was quenched with 2-propanol (1.5 ml) and the 
solvent was removed in vacuo. The resulting yellow/white gum was 
purified by column chromatography (1000 ml SiO2, eluted sequentially 
with 99:1 and then 98:2 CH2CI2:MeOH) to afford 2.9 g of 2a as a col- 
orless foam (this product was contaminated with triphenylphosphine 
oxide and the diethyl hydrazine-N,N'-dicarboxylate ester byproducts). 
The crude product wan trifluoroacetylated without further purification. 
An analytical sample was prepared using preparative thin-layer chro- 
matography (TLC; 1.0mm thickness, developed with 95:5 
CH2CI2:MeOH). Rf 0.35 (CH2CI2:MeOH 95:5); 1H NMR (400 MHz, 
CDCI 3) (5 1.58 (d, 6H, 6.8 Hz), 4.70 (sept., 1 H, 6.8 Hz), 5.29 (br s, 2H), 
7.85 (s, 1H); 13C NMR (101 MHz, CDCI 3) (5 22.3, 47.1, 125.6, 140.0, 
151.1, 153.4, 158.8; mass spectrum (FAB +) m/e 212 (MH+); HRMS 
calc'd for (CsH10N&CI)'H+: 212.0703, found: 212.0?03. 
2-Trifluoroacetamino-6-chloro-9-isopropylpurine (2b). 2-Amino-6-chloro- 
9-isopropylpurine (3.11 g, 14.7 mmol) was dissolved in distilled CH2CI 2 
(29 ml) and the resulting solution cooled to 0°C. Trifluoroacetic anhydride 
(6.2ml, 44mmol) was added dropwise. The reaction mixture was 
warmed to rt over 3 h, concentrated in vacuo and dried further under high 
vacuum. The crude product was purified by chromatography (600 ml 
SiO2, eluted with 20:80 EtOAc:CH2CI 2) to yield 4.0 g of 2b (88%). Rf 
0.41 (CH2CI2:MeOH 95:5); 1H NMR (400 MHz, CDCI 3) (5 1.68 (d, 6H, 
6.8 Hz), 4.92 (sept., 1 H, 6.8 Hz), 8.59 (s, 1H), 10.20 (s, 1H). 
2- (2-tert-Butyldimethylsilyloxyethylamino)-6-chloro-9-isopropylpurine 
(3). Trifluoroacetamide 2b (4.52 g, 14.7 mmol), 2-tert-butyldimethylsilyl- 
oxyethanol (5.18 g, 29.4 mmol) and triphenylphosphine (7.71 g, 
29.4 mmol) were dissolved in freshly distilled THF (500 ml). The reaction 
mixture was stirred and cooled to 0°C and diethyl azodicarboxylate 
(2.31 ml, 14.7 mmol) was added dropwise over 5 min. The reaction 
mixture was warmed to rt, stirred for 12 h, and concentrated in vacuo to 
yield a yellow oil. This crude reaction mixture was redissolved in methanol 
(50 ml) and combined with an aqueous solution of potassium carbonate 
(16 ml, 1.0 M). The hydrolysis was complete within 1 h as judged by the 
disappearance of the trifluoroacetamide (Rf 0.74 EtOAc:hexane 75:25) 
by TLC. The resulting white slurry was partitioned between ethyl acetate 
and water (300 ml of each) and the organic layer collected, dried over 
sodium sulfate and concentrated in vacuo. The resulting oil was purified 
by column chromatography (1000 ml SiO2, eluted with EtOAc:CH2CI 2 
5:95) to yield 3.0g of 3 (55%). Rf0.26 (EtOAc:hexane 1:1); 1H NMR 
(500 MHz, CDCI 3) (5 0.06 (s, 6H), 0.90 (s, 9H), 1.57 (d, 6H, 6.8 Hz), 
3.57 (q, 2H, 5.6 Hz), 3.80 (t, 2H, 5.6 Hz), 4.69 (sept., 1 H, 6.8 Hz), 5.49 
(bs, 1H), 7.76 (s, 1H); 13C NMR (126 MHz, CDCI 3) (5-4.8, 21.1, 24.8, 
25.0, 43.5, 4?.2, 60.2, 123.1, 3g.7, 149.8, 152.7, 158.5; mass spec- 
trum for C16H28NsCIOSi (FAB+) ' m/e 371 (MH+). 
2-(2-Hydroxyethylamino)-6-anilino-9-isopropylpurine (42). Compound 
3 (24 mg, 0.06 mmol), aniline (24 ~tl, 0.26 mmol) and diisopropylethy- 
lamine (45 #1, 0.26 mmol) were dissolved in nBuOH (1.5 ml). The reac- 
tion mixture was stirred at 90°C for 12 h and then concentrated in 
vacuo. The crude product was dissolved in a mixture of THF (200 pl), 
water (200 pl) and acetic acid (600 I-d). The reaction mixture was stirred 
at rt for 12 h, concentrated in vacuo and azeotroped 3 x with methanol 
(3 ml x 3). The crude product was purified by preparative TLC (2 plates 
1.0 mm thickness, developed twice with 60:40 EtOAc:hexane) to yield 
16.4 mg (810/o) of 42 as an oil. 1H NMR (400 MHz, CDCI3): (5 1.52 (d, 
6H, 6.8 Hz), 3.59-3.63 (m, 2H), 3.84-3.87 (m, 2H), 4.5?-4.65 (m, 
1H), 5.51-5.53 (m, 1H), 7.03-7.07 (m, 1H), 7.27-7.33 (m, 2H), 7.59 
(s, 1H), 7.75-?.77 (m, 2H), 8.16 (s, 1H); 13C NMR (126 MHz, CDCI 3) (5 
22.4, 45.1, 46.6, 63.8, 114.8, 120.2, 123.0, 128.7, 135.0, 139.1, 
150.5, 152.4, 160.6; mass spectrum (FAB +) m/e 313 (MH+); HRMS 
calc'd for (C16H20N6CI)H+: 313.1777, found: 313.1778. 
2-Fluoro-6-chloro-9-isopropylpurine (4). Anhydrous THF (60 ml) was 
added under nitrogen to a flame-dried flank containing 2-fluoro-6- 
chloropurine (0.90 g, 5.2 mmol) and triphenylphosphine (3.0g, 
10.4 mmol). To this was added 2-propanol (800 pl, 10.4 mmol), after 
which the solution was cooled to -10°C. Following the dropwise addi- 
tion of diethyl azodicarboxylate (850p.I, 10.4 mmol), the mixture was 
warmed gradually to rt. After 12 h, the reaction was quenched with water 
(500 pl) and the solvent removed in vacuo. The resulting yellow oil was 
purified by column chromatography (600 ml SiO2, eluted with 100o/0 
CH2CI2). The resulting solid was triturated with methanol (to remove the 
diethyl hydrazine-N,N'-dicarboxylate ester byproducts) to yield 630 mg 
(57 o/0) of 4 as a white crystalline solid. Rf 0.54 (MeOH:CH2CI 2 10:90); 
1H NMR (500 MHz, CDCI3): (5 1.65 (d, 6H, J=6.8 Hz), 4.85 (sept, 1H, 
6.8 Hz), 8.15 (s, 1H); 13C NMR (126 MHz, CDCI3): (5 22.3, 48.4, 130.5, 
143.7, 152.3, 153.1, 156.9 (Jc-F---- 870 Hz); mass spectrum (El +) m/e 
214 (M+); anal. calc'd for CaHsN4FCI: C, 44.7?; H, 3.?6; N, 26.10; CI, 
16.52. Found: C, 44.97; H, 3.76; N, 26.09; CI 16.37. 
2-Fluoro-6-(3-chloroanilino)-9-isopropylpurine (5). A mixture of 4 
(3.75 g, 17.5 mmol), 3-chloroaniline (1.85 ml, 17.5 mmol) and diiso- 
propylethylamine (3.05 ml, 17.5 mmol) were dissolved in n-butanol in a 
sealed tube. After 12 h at 140°C, the solvent was evaporated in vacuo, 
the crude product triturated with water, filtered and rinsed with CH2CI 2 
and ether to yield 3.11 g (58O/o) of 5 as a white solid. Rf 0.66 
(MeOH:CH2CI 2 5:95); 1H NMR (400MHz, CDCI 3) 8 1.61 (d, 6H, 
J =6.8 Hz), 4.78 (sept., 1H, 6.8 Hz), 7.08 (d, 1H, J=6.2 Hz), 7.26-7.30 
(m, 1H), 7.64 (d, 1H, 8.2Hz), 7.84 (s, 2H), 8.72 (s, 1H); 13C NMR 
(101 MHz, CDCI 3) (5 22.4, 4?.5, 118.9, 120.4, 123.8, 129.9, 134.4, 
138.9, 13g.3,150.7, 153.2(Jc_ F =20Hz), 157.4(Jc_F=1g Hz), 159.5; 
mass spectrum (El +) m/e 305 (M+); HRMS calc'd for (C14H13NsCIF)H+: 
305.0844, found: 305.0839; anal. calc'd for C14H13NsCIF: C, 55.00; H 
4.29; N, 22.91. Found: C, 55.35, H, 4.37, N, 23.10. 
2-(1R-Isopropyl-2-hydroxyethylamino)-6-(3-chloroanilino)-9 isopropyl- 
purine (60). Compound 6 (1.55 g, 5.1 mmol), R(-)2-amino-3-methyl-1- 
butanol (559 pl, 5.1 mmol) and diisopropylethylamine (892 pl, 
5.1 mmol) were dissolved in n-butanol (1 ml) in a sealed tube. After 
heating the reaction mixture for 12 h at 140°C, the n-butanol was 
removed in vacuo and the crude product purified by column chro- 
matography (400 ml SiO2, eluted with 99:1 CH2CI2:MeOH) to yield 
1.2g (57%) of 60 as a white solid. RfO.2 (MeOH:CH2CI 2 5:95); 1H 
NMR (500 MHz, CDCI 3) (5 1.04 (d, 6H, 2.0, 6.8 Hz), 1.51 (d, 6H, 2.0, 
6.8 Hz), 1.97-2.05 (m, 1H), 3.72-3.77 (m, 1H), 3.91-4.00 (m, 2H), 
4.53 (sept., 1 H, 6.8 Hz), 5.06 (d, 1 H, 7.8 Hz), 6.97-?.00 (m, 1H), 7.20 
(t, 3H, 8.1 Hz), 7.42 (d, 1H, 7.9 Hz), 7.55 (s, 1H), 8.00 (s, 1H), 8.03 (s, 
1H); 13C NMR (126 MHz, CDCI 3) (5 18.9, 19.4, 22.4, 30.0, 46.5, 59.6, 
65.1, 114.9, 117.5, 119.6, 122.4, 129.6, 134.2, 135.1, 140.5, 150.8, 
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151.8, 159.?; mass spectrum (FAB +) m/e 389 (MH+); HRMS calc'd 
for (C19H25NsOCI)H+: 389.1857, found, 389.1859; anal. calc'd for 
01sH25NsOCI: C, 58.68; H, 6.48; N, 21.61; CI, 9.12; O, 4.11. Found: 
C, 58.54; H, 6.61; N, 21.58; CI, 9.10; O, 3.96. 
2-Fluoro-6-(N,N'-(methyl),(3-chloroanilino)-9-isopropylpurine (6). A 
solution of 5 (110 mg, 0.36 mmol) in dry DMF (1.5 ml) was added 
dropwise to a suspension of Nail (18 rag, 0.43 mmol) in dry DMF 
(1 ml). This mixture was stirred for 20 min at rt, after which a solution of 
methyl iodide (35 #1, 0.36 mmol) in DMF (0.5 ml) was added slowly. 
After stirring 12 h, the DMF was removed in vacuo and the crude 
product purified by chromatography (200 ml SiO2, eluted with 98:2 
CH2CI2:MeOH) to yield 115 mg of 6 (100%) as a white solid. Rf 0.61 
(MeOH:CH2CI 2 5:95); 1H NMR (CDCI3, 400 MHz) 5 1.47 (d, 6H, 
6.8 Hz), 3.73 (s, 3H), 4.68 (sept., 1H, 6.8Hz), ?.15-?.38 (ml 5H), 
7.63 (s, 1H); mass spectrum (FAB +) m/e 320 (MH+); HRMS calc'd for 
(C1sH15NsCIF)H+: 320.1080, found, 320.1080. 
2-(1R-isopropyl-2-hydroxyethylamino)-6-(N, N "-(methyl), (3-chloro- 
anilino)-9-isopropylpurine (60Me). Procedure same as that used to 
prepare compound 60. Rf0.25 (MeOH:CH2CI 2 5:95); 1HNMR 
(300 MHz, CDCI3) 6 0.99 (d, 6H, 6.8 Hz), 1.51 (d, 6H, 6.8 Hz), 1.65 (br 
s, 2H), 1.94 (sept., 1H~ 6.8 Hz), 3.61-3.73 (m, 2H), 3.79 (s, 3H), 4.62 
(sept, 1H, 6.8 Hz), 4.83-4.85 (m, 1H), ?.19-?.36 (m, 4H), ?.49 (s, 1H); 
13C NMR (?5 MHz, CDCI 3) 8 19.0, 19.4, 22.4, 22.5, 30.0, 39.8, 46.1, 
59.8, 66.2, 115.6, 124.?, 126.1, 127.1, 129.?, 134.1, 134.5, 146.9, 
152.5, 154.4, 159.3; mass spectrum (FAB +) m/e 403 (MH+); HRMS 
calc'd for (C20H27N6OCI)H+: 403.2013, found, 403.2013. 
2 -Fluoro -6- (N-tert-butoxycarbonyl-3 chloroanilino) -9-isopropylpurine 
(7). Compound 5 (169mg, 0.55mmol), di-tert-butyldicarbonate 
(219 mg, 1.0 mmol), diisopropylethylamine (0.8 ml, 4.6 mmol) and 
dimethylaminopyridine (36 mg) were dissolved in THF (10 ml). After the 
reaction mixture was stirred at rt for 5 h, the solvent was removed in 
vacuo and the crude product was purified by column chromatography 
(80 ml SiO2, eluted with ethyl acetate-hexane gradient) to yield 1 ?6 mg 
(?9%) of ? as a white solid. Rf0.4 (EtOAc:hexane 1:2); 1H NMR 
(500 MHz, CDCI 3) ~ 1.47 (s, 9H), 1.63 (d, 6H, ?.0 Hz), 4.84 (m, 1 H), 
?.19-7.33 (m, 4H), 8.06 (S, 1H); mass spectrum (FAB +) role 406.1 
(MH+); HRMS calc'd for (Cl~H21NsO2FCI)H+: 406.1446, Found 
406.1437; anal. calc'd for C~gH2~NsO2FCI: C 56.23; H, 5.22; N, 
17.26. Found: C, 56.48; H, 5.4?; N, 16.99. 
2-(1 R-Isopropyl-2-hydroxyethylamino)-6-(N-tert-butoxycarbonyl-3- 
chloroanilino)-9-isopropylpurine (8.). To a stirring solution of 7 (108 rag, 
0.2? mmol) in DMSO (10 ml) was added R(-)2-amino-3-methyl-1-butanol 
(202 rag, 1.96 mmol) and diisopropylethylamine (1 ml, 5.7 mmol). After 
heating for 12 h at 80°C, the DMSO was removed in vacuo with heating 
to 70°C, and the crude product purified by chromatography (400 ml 
SiO2, eluted with ethyl acetate-hexane gradient) to yield 88 mg (6?O/o) of 
8 as an oil. Rf0.4 (EtOAc:hexane 2:1); 1H NMR (500MHz, CDCI3) 5 
0.95 (d, 3H, 7.0 Hz), 0.96 (d, 3H, 7.0 Hz), 1.47 (S, 9H), 1.57 (d, 3H, 
7.0 Hz), 1.58 (d, 3H, ?.0 Hz), 1.94 (m, 1H), 3.44 (bs, 1 H), 3.65 (m, 1 H), 
3.75-3.?? (m, 2H), 4.68 (m, 1H), 5.18 (d, 1H, 8.0 Hz), ?.21-?.31 (m, 
4H), ?.77 (S, 1H); mass spectrum (FAB +) m/e 489.2 (MH+); HRMS 
calc'd for (C24H33NsO3CI)H+: 489.2381, found 489.237?. 
2-(1R-isopropyl-2-dimethyl-tert-butylsilyloxyethylamino)-6-(N tert- 
butoxycarbonyl-3-chloroanilino)-9-isopropylpurine (9). Compound 8 
(40 mg, 0.081 mmol), tert-butyldimethylsilyl chloride (200 rag, 
1.33 mmol) and imidazole (380 mg, 5.58 mmol) were dissolved in THF 
(10 ml) and stirred at rt. After 24 h, a precipitate had developed which 
was removed by filtration. The solid byproduct was washed with THF, 
concentrated in vacuo and purified by preparative thin layer chromatogra- 
phy (20 x 20 cm, 0.5 mm, ethyl acetate-hexane 1:1) to give 33 mg (68%) 
of 9 as an oil. Rf0.7 (EtOAc:hexane 1:1); 1H NMR (500 MHz, CDCI3) 6 
-0.04 (s, 3H), -0.02 (s, 3H), 0.84 (s, 9H), 0.88-0.92 (m, 6H), 1.44 (s, 
9H), 1.55 (d, 3H, 7.0 Hz), 1.56 (d, 3H, ?.0 Hz), 1.97 (br, 1H), 3.59 (m, 
1H), 3.?0 (m, 1H), 3.82 (m, 1H), 4.69 (m, 1H), 5.06 (d, 1H, 9.5 Hz), 
7.16-7.30 (m, 4H), ?.73 (s, 1H); mass spectrum (FAB +) m/e 603.3 
(MH+); HRMS calc'd for (C3oH4?NsO3CISi)H+: 603.3246, found 
603.324?; anal. calc'd for CsoH47NsO3CISi: C 59.?3; H, ?.85; N, 13.93. 
Found: C, 59.83; H, 8.04; N, 13.87. 
2-(N-Benzyl- 1R-isopropyl-2-hydroxyethylamino)-6-(3-chloroanilino)-9- 
isopropylpurine (301). To a solution of 9 (33 mg, 0.055 mmol) in DMF 
(? ml) was added sequentially sodium hydride (60% dispersed in mineral 
oil, 94 mg, 2.4 mmol), benzyl bromide (100 #1, 0.84 mmol) and tetrabuty- 
lammonium iodide (68 mg, 0.18 mmol) at rt under nitrogen. The reaction 
mixture was stirred for 1 ? h and then diluted with CH2CI 2 (50 ml) and ill- 
tered through SiO 2 (100 ml). The filtrate was concentrated in vacuo, and 
hydrolysed with p-toluenesulfonic acid (30 mg) in a mixture of MeOH- 
CH2CI 2 (1:1, 20 ml) at rt for 24 h. After removal of the solvent, the 
product was purified using preparative thin layer chromatography 
(20 x 20 cm, 0.5 mm, ethyl acetate-hexane 2:1) to give 5 mg (19%) of 
301 as an oil. Rf 0.2 (EtOAc:hexane 2:1); 1H NMR (500 MHz, CDCI3) 
0.87 (d, 3H, 6.5 Hz), 1.08 (d, 3H, 6.5 Hz), 1.25 (s, 6H), 2.40 (m, 1H), 
3.79 (m, 1H), 3.88 (m, 2H), 4.6? (m, 1H), 4.85 (brs, 2H), 6.99 (br, 1H), 
?.12-?.96 (m, 10H); mass spectrum (FAB +) m/e 4?9.2 (MH+); HRMS 
calc'd for (026H31NsOCI)H+: 4?9.2326, found 479.2321. 
Supplementary material  
General synthetic methods and spectroscopic data for all compounds 
included in the main text, as well as details of solid-phase synthesis of 
representative library members and all biological assays (kinase assays, 
cell culture, cell viability assays, cell-cycle and apoptosis assays, flow 
cytometry and cell-cycle analysis and immunocytochemistry) are pub- 
lished with the online version of this paper. 
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